Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Not yet recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 35INDUSTRY 7OTHER_GOV 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Stomach Neoplasms 4Carcinoma, Hepatocellular 4Esophageal Neoplasms 3Nasopharyngeal Carcinoma 2Immunotherapy 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2SCLC, Extensive Stage 1Mid-low Rectal Cancer 1Melanoma 1Locally Advanced Rectal Cancer 1Laryngeal Neoplasms 1Immunotherapy Gastrict Cancer 1Hypopharyngeal Neoplasms 1Colonic Neoplasms 1Advanced Non-small-cell Lung Cancer 1

Interventions

tislelizumab 4Sorafenib 3Propranolol 3ledipasvir 2entecavir 2donafenib 2Sofosbuvir 2Ribavirin 2Radiotherapy 2Proton Therapy 2Bevacizumab 2sitravatinib 1polysaccharide MGN3 1palbociclib 1lenvatinib 1lens intermediate filament proteins 1ledipasvir, sofosbuvir drug combination 1envafolimab 1elbasvir-grazoprevir drug combination 1daclatasvir 1atezolizumab 1apatinib 1anlotinib 1Vitamin D 1Urination 1Tyrosine Kinase Inhibitors 1Simeprevir 1Raltegravir Potassium 1Radiosurgery 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER_GOV × Carcinoma, Hepatocellular × tislelizumab × Clear all
NCT07363512 2026-01-23

Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus

Henan Cancer Hospital

Phase 2 Not yet recruiting
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05897138 2023-06-13

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Fujian Cancer Hospital

Phase 2 Not yet recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05407519 2023-03-22

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Anhui Provincial Hospital

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05545124 2022-09-19

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Henan Cancer Hospital

Phase 2 Unknown
32 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡